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1. Introduction 
The antitumour antibiotic bleomycin binds to and 
degrades DNA both in vivo and in vitro. This damaging 
activity has been shown to be dependent on the che- 
lation of ferrous ions, which under aerobic conditions 
leads to the formation of the hydroxyl radical [ 1,2]. 
This damage can be measured by the release of mal- 
ondialdehyde (MDA) which reacts with thiobarbituric 
acid (TBA) to give the chromogenic MDA-TBA ad- 
duct [3]. Ironcatalysed autoxidation of polyunsatu- 
rated fatty acids results in the formation of numerous 
lipid peroxides and longchain aldehydes. When sub- 
jected to acid conditions and heating during the TBA 
test these decompose to give malondialdehyde and 
the same MDA-TBA adduct. Metal-ion catalysed per- 
oxidation of phospholipid like that of bleomycin 
iron damage to DNA has been shown to involve reduc- 
tion intermediates of dioxygen [4]. Unlike bleomy- 
cir-iron-mediated damage to DNA, which takes only 
minutes, lipid peroxidation is a slower autocatalytic 
reaction characterised by a long induction period 
during which changes do not appear to take place. 
Previous studies have shown that the antioxidant 
propyl gallate greatly enhances bleomycin-iron- 
dependent damage to DNA resulting in the increased 
formation of the MDA-TBA adduct [5]. This work 
has now been extended to examine the effect of a 
variety of water-soluble mono-, di- and trihydroxy- 
phenols on the iron-catalysed free radical damage to 
lipids and DNA resulting in the formation of the 
MDA-TBA adduct. Phenols with reducing properties 
inhibited lipid peroxidation but greatly enhanced 
bleomycin-iron-dependent damage to DNA. One 
possible implication of this finding is that the clinical 
administration of phenolic compounds with reducing 
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properties could potentiate the tumour damaging 
properties of the drug bleomycin while at the same 
time protecting normal lipid membranes from delete- 
rious free radical damage. 
2. Materials and methods 
2.1. Reagents 
Bathophenanthroline sulphonate, nitro blue tetra- 
zolium (NBT) D,L-dihydroxyphenyl alanine (DOPA), 
L-adrenaline, catechol, phloroglucinol, L-tyrosine and 
DNA calf thymus type 1 were obtained from Sigma 
Chemical Co. Bleomycin sulphate complex was from 
Lundbeck Ltd. All other chemicals were of the highest 
grades available and obtained from BDH Ltd. 
2.2. Peroxidation of phospholipid 
The phospholipid and liposomes were prepared as 
in [6], the latter were used as a substrate for the lipid 
peroxidation studies. Phospholipid (5 mg/ml) was 
vortex-mixed with 0.15 M NaCl, buffered to pH 7.4 
with sodium hydrogen carbonate, for 2 min and the 
preparation allowed to swell for 1 h at 4°C under ni- 
trogen. Incubation mixtures consisted of 0.5 ml phos- 
pholipid liposomes, 0.1 ml phenolic compound, 0.3 
ml phosphate saline buffer (pH 7.4) (0.024 M phos- 
phate, 0.15 M NaCl) and 0.1 ml ferrous ions 0.5 mM 
freshly prepared. Samples were incubated for 2 h at 
37°C followed by the addition of 1 ml 25% (v/v) HCl 
and 1 ml 1% TBA reagent then heated at 100°C for 
15 min to develop the MDA-TBA chromogen which 
was read at 532 nm. 
2.3. Bleomycin-iron-mediated degradation of DNA 
DNA (0.5 ml) (1 mg/ml in 0.15 M NaCl, buffered 
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to pH 7.4 with sodium hydrogen carbonate) together 
with 0.1 ml 1 mg bleomycin/mI, 0.2 ml phosphate- 
saline buffer (pH 7.4) and 0.1 ml phenohc compound 
were mixed together and the reaction started by the 
addition of 0.1 ml 0.5 mM ferrous ions. The tubes 
were incubated at 37’C for 20 min followed by the 
addition of 1 ml 25% (v/v) HCl and 1 ml of 1% TBA 
reagent. The tubes were heated at 100°C for 15 min 
to develop the MDA-TBA chromogen which was 
read at 532 nm. 
2.4. Iron-reducing properties of phenols 
The method used for measuring the ferric ion re- 
ducing properties of the phenols was based on a vita- 
min E assay procedure 173. Bathophenanthroli~e sul- 
phonate (0.1 ml, 1 mg/ml), 0.1 ml ferric ions 0.5 mM 
and 0.1 ml phenolic compound were reacted together 
at room temperature for a few minutes in 0.6 ml phos- 
phate-saline buffer (pH 7.4) before the addition of 
0.1 ml 6% (v/v) orthophosphoric acid. Distilled water 
(2.0 ml) was added to each tube and the absorbance 
at 532 nm measured in a spectrophotometer. 
2.5. Reduction of NBT 
Phosphate-saline buffer (0.6 ml, pH 7.4), 0.1 ml 
EDTA0.1 mM,O.l mlTritonX-100 16%(v~v)andO.l 
ml NBT 1 mM were mixed together before the addition 
of 0.1 ml test phenolic compound. The tubes were 
incubated at 37°C for 15 min followed by the addi- 
tion of 2.0 ml phosphate-saline buffer (pH 7.4) and 
the absorbance read at 540 nm. 
3. Results 
Bovine brain phospholipids containing high levels 
of unsaturated fatty acids were used as a substrate in 
the form of multi-lame~a liposomal membranes. Fol- 
lowing ironcatalysed peroxidation, an MDA-TBA 
adduct was formed and measured as in (61. Addition 
of a variety of mono-, di- and trihydroxyphenols 
either inhibited or had no effect on the iron-catalysed 
lipid peroxidation (table 1). Iron chelated by bleomy- 
tin enhanced lipid peroxidation by nearly 40% when 
the ironfbleomycin molar ratio approached 1. Similar 
enhancement of lipid peroxidation by chelated iron 
has been described for EDTA and diethylenetriamine- 
pentaacetic acid (DETAPAC) and bathophenanthro- 
line sulphonate [8]. Addition of phenols to bleomy- 
tin-ironcatalysed lipid peroxidation gave essentailly 
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Table 1 
Inhibition of MDA formation during the iron-catalysed 





Ferrous ions Bleomycit- 
ferrous ions 
A 582 % Inhibition A,,, % Inhibition 
0.35 0.50 
Phenol No change No change 
Tyrosine No change No change 
Catechol 0.16 56% 0.13 14% 
Adrenaline 0.21 25% 0.22 56% 
Dihydroxyphenyl 
alanine (DOPA) 0.19 46% 0.35 30% 
Resorcinol No change No change 
Quinol 0.22 38% 0.32 37% 
Pyrogallol 0.22 38% 0.42 15% 
Phloroglucinol No change No change 
Propyl gallate 0.17 54% 0.18 63% 
-.. 
Peroxidation of phospho~pid catalysed by ferrous ions 0.05 
mM and by 0.1 mg bleomycin~~ together with ferrous ions 
0.05 mM. Inhibition by phenols 0.1 mM is expressed as a 
percentage of the control value, to which phenols were not 
added, based on the mean of 4 seperate assays 
the same pattern of in~bition seen with iron alone, 
but with different degrees of inhibition (table 1). 
The TBA-MDA adduct formed from DNA after 
bleomycin-iron damage was measured by the same 
method used for the lipid MDA-TBA adduct. Those 
phenolic compounds which reacted as the most effec- 
tive antio~dants against iron~atalysed lipid peroxida- 
tion were the most reactive pro-oxidants in the bleo- 
mycin-ironcatalysed damage to DNA (table 2). In 
the absence of added phenols but presence of bleo- 
mycin only ferrous ions were capable of mediating 
this DNA damage. Activity with ferric and enhance- 
ment with ferrous ions could be related to the reduc- 
ing properties of the phenols (table 3). Measurement 
of the reduction of ferric ions as well as that of NBT 
indicated that the reducing properties of the phenols 
were essential to both its lipid antioxidant properties 
as well as to the enhancement of DNA damage by 
bleomyc~-iron. 
4. Discussion 
Malond~ldehyde can be formed by iron-catalysed 
damage to polyunsaturated fatty acids as well as to 
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Table 2 
Enhancement of MDA formation during bleomycin-iron 





ferrous ions ferric ions 
A 532 % Enhance- Increase in A,,, 
ment 
Control 0.42 0 
Phenol No change No change 
Tyrosine No change No change 
Catechol 0.63 49% 0.063 
Adrenaline 0.60 44% 0.355 
Dihydroxyphenyl 
alanine (DOPA) 1.82 333% 0.480 
Resorcinol No change No change 
Quinol 1.78 326% 0.250 
PyrogaBol 1.85 342% 1.600 
Phloroglucinol No change No change 
Propyl gallate 1.14 171% 0.393 
Damage to DNA catalysed by 0.1 mg bleomycin/ml together 
with ferrous 0.05 mM or ferric ions 0.05 mM. Bleomycin- 
ferrous ion enhancement expressed as a percentage of the 
control value based on the mean of 4 separate assays. Bleo- 
mycin-ferric ion damage xpressed as the change in absor- 
bance at 532 nm 
DNA. In both instances, evidence points to a dioxygen- 
dependent free radical mechanism. The peroxidation 
of unsaturated fatty acids has been studied in great 
detail during the last 40 years particularly with refer- 
ence to the edible oils and fats of our foodstuff. Hy- 
drogen abstraction by a free radical thereby leads to 
an autocatalytic sequence which eventually destroys 
the lipid molecule : 
LH (lipid) t R’ (free radical) + L’ (lipid radical) + RH 
L’ t O2 -+ LOO’ (lipid peroxy radical) 
LOO’ + LH + LOOH (lipid hydroperoxide) + L’ 
Transition metal ions, particularly iron and copper, 
can initiate radical formation as well as catalyse the 
branching sequence by decomposing lipid peroxides 
to further free radical intermediates. Most of the scav- 
enging lipid antioxidants, such as the phenols, are re- 
ducing substances which act by hydrogen donation. 
Early studies [9], still vahd today, suggest hat the 
reducing antioxidants (AH) react primarily with the 
lipid peroxy radicals (LOO’) terminating the radical 
Table 3 
Reducing properties of phenols 
Phenolic Reduction of ferric ions Reduction 
compound (measured as the BPS- of NBT 
ferrous complex) A 540 
A 532 
Phenol No change No change 
Tyrosine No change No change 
Catechol 0.190 0.022 
Adrenaline 0.170 0.126 
Dihydroxyphenyl 
alanine (DOPA) 0.180 0.148 
Resorcinol No change No change 
Quinol 0.200 0.115 
Pyrogallol 0.215 0.640 
Phloroghtcinol No change No change 
Propyl gallate 0.200 0.100 
Reduction of 0.05 mM ferric ions and 0.1 mM NBT by 0.1 
mM phenols 
sequence by forming stable complexes (2A) or new 
radicals (A’) which do not continue the chain reac- 
tion : 
AH + LOO’ + LOOH + A 
A’ + A’ + 2A 
Application of the TBA test to peroxidised lipid 
results in the formation of an MDA-TBA adduct; 
most of the MDA being derived by the acid or thermal 
decomposition of peroxides during the test tube reac- 
tion. When the same test is applied to DNA damaged 
by bleomycin-iron it is possible that the MDA form- 
ing the TBA adduct is ‘free MDA’ derived from the 
deoxyribose sugar moiety of DNA. This iron-dioxy- 
gen-dependent damage to DNA is thought to occur 
by an ironcatalysed Haber-Weiss reaction which results 
in the formation of a hydroxyl radical opposite the 
deoxyribose sugar [ lo,1 11. Attempts to inhibit this 
reaction, on linear duplex DNA, with specific and 
non-specific radical scavengers have been unsuccess- 
ful [5], with only metal chelators preventing such 
damage. This can be partly explained by the catalytic 
nature of the bleomycin-iron damage to DNA [ 121. 
Bleomycin has been shown to act as a ‘ferroxidase’ 
catalysing the rapid oxidation of ferrous ions to the 
ferric state [ 131. This ‘enzymic’ free radical producing 
reaction has here been shown to be enhanced by re- 
ducing phenols which recycle iron to the ferrous state 
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via a radical intermediate or the superoxide radical. References 
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